SaiXifu ® Hydroxychloroquine sulfate tablets
Selected Varieties of the 10th Volume-Based Procurement
The National Essential Drugs, Medicare Category B
[Drug Name]
Generic name: Hydroxychloroquine sulfate tablets
[Indications]
Rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases triggered or aggravated by sunlight.
[Dosage and Administration ]
Oral tablets.
• Adults (including elderly):
Initial dose: 400 mg daily in divided doses. Once no further improvement is observed, reduce to a maintenance dose of 200 mg daily. If the therapeutic response diminishes, increase to 400 mg daily. The minimum effective dose should be used, not exceeding 6.5 mg/kg/day (based on ideal body weight, not actual body weight) or 400 mg/day, whichever is lower.
• Children:
The minimum effective dose should be used, not exceeding 6.5 mg/kg/day (based on ideal body weight) or 400 mg/day, whichever is lower. Contraindicated in children under 6 years old. The 200 mg tablets are unsuitable for children weighing less than 35 kg.
Each dose should be taken with food or milk.
Hydroxychloroquine has a cumulative effect and may require several weeks to exert therapeutic benefits, while mild adverse effects may occur earlier. If no improvement in rheumatic diseases is observed after 6 months, treatment should be discontinued. For photosensitivity disorders, treatment should be restricted to periods of maximal sun exposure.
[Contraindications]
• Known hypersensitivity to 4-aminoquinoline compounds.
• Pre-existing maculopathy.
• Children under 6 years (200 mg tablets unsuitable for children <35 kg).
[Specification]
0.2 g
[Validity Period]
36 months
[Approval Number]
National Medical Approval Number: H20234411
Consultation hotline: +86 591 83512959
